Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Isotechnika Pharma Inc IPHAF

Healthcare Biotechnology


GREY:IPHAF - Post by User

Isotechnika Pharma Inc
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(0)
•••
Post by narcissiston Oct 18, 2011 9:25am
422 Views
Post# 19158449

Positive SA from EMA

Positive SA from EMA

Isotechnika Receives Positive Scientific Advice From The European Medicines Agency


https://www.newswire.ca/en/story/860521/isotechnika-receives-positive-scientific-advice-from-the-european-medicines-agency

It's a good news/bad news day. The LUX application with EMA was also withdrawn today.

EMA: Lux Biosciences Withdraws Marketing Authorization Application For Luveniq



https://www.newswire.ca/en/story/860521/isotechnika-receives-positive-scientific-advice-from-the-european-medicines-agency
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities